Click to view our accessibility statement Delivering on HopeTM
  • About Us
    • About Neurocrine
    • Leadership Team
      • Management Team
      • Board of Directors
    • Culture & Values
      • Patient Access & Pricing
      • Diversity & Equality
    • News & Events
    • Webcasts & Presentations
    • Contact Us
  • Patients & Families
    • Overview
    • Tardive Dyskinesia
    • Parkinson’s Disease
    • Congenital Adrenal Hyperplasia
    • Chorea in Huntington Disease
    • Women’s Health
    • Psychiatric Disorders
  • Products
  • Pipeline
    • OVERVIEW
    • Congenital Adrenal Hyperplasia
      • Crinecerfont
        • Clinical Trials
    • Chorea in Huntington Disease
      • Valbenazine
        • Clinical Trials
    • Women’s Health
      • Polycystic Ovary Syndrome
    • Psychiatric Disorders
      • Schizophrenia
        • NBI-1065844 (TAK-831)
          • Clinical Trials
      • Treatment-Resistant Depression
        • NBI-1065845 (TAK-653)
      • Anhedonia
        • NBI-1065846 (TAK-041)
    • Epilepsy
      • NBI-921352 (XEN901)
      • NBI-827104 (ACT-709478)
    • Additional Pipeline Programs
  • Careers
    • Overview
    • Culture and Values
    • Benefits
    • Recruitment Agencies
  • Investors
    • Press Releases
    • Stock Quote
    • SEC Filings
    • Shareholder Contacts
    • Partners/Collaborators
    • Annual Meeting
    • Online Annual Reports
    • Ownership
    • Email Alerts
    • Corporate Governance
    • Corporate Sustainability
    • Webcasts & Presentations
  • Contact Us

Site Map

Pages

    • Home
    • Neurocrine Accessibility Statement
    • https://careers-neurocrine.icims.com/jobs/intro
    • Investors
      • Corporate Sustainability
      • Partners/Collaborators
      • Annual Meeting
      • Online Annual Reports
      • Corporate Governance
    • Terms & Conditions
    • CCPA Data Request
    • About Us
      • Culture & Values
      • Patient Access & Pricing
      • Diversity & Equality
      • About Neurocrine
      • Leadership Team
        • Board of Directors
        • Management Team
      • Webcasts & Presentations
      • Contact Us
      • Privacy Policy - Example (Private)
      • Privacy Policy
      • Cookie Policy
    • Patients & Families
      • Psychiatric Disorders
        • Psychiatric Disorders
          • Treatment-Resistant Depression
        • Anhedonia
      • Women's Health
      • Overview
      • Tardive Dyskinesia
      • Chorea in Huntington Disease
      • Parkinson’s Disease
      • Congenital Adrenal Hyperplasia
    • Products
    • Pipeline
      • Psychiatric Disorders
        • Schizophrenia
          • NBI-1065844 (TAK-831)
            • Clinical Trials
        • Treatment-Resistant Depression
          • NBI-1065845 (TAK-653)
        • Anhedonia
          • NBI-1065846 (TAK-041)
      • Chorea in Huntington Disease
        • Valbenazine
          • Clinical Trials
      • Congenital Adrenal Hyperplasia
        • Crinecerfont
        • Clinical Trials
      • Additional Pipeline Programs
      • Commercially Available and Pipeline Candidates
      • Elagolix – GnRH Antagonist
        • Polycystic Ovary Syndrome
      • Movement Disorders
      • Epilepsy
        • NBI-921352 (XEN901)
        • NBI-827104 (ACT-709478)
    • Careers
      • Culture & Values: Delivering on Hope TM
      • Overview
      • Benefits
      • Recruitment Agencies

About Us

  • About Neurocrine
  • Leadership Team
    • Management Team
    • Board of Directors
  • Culture & Values
    • Patient Access & Pricing
    • Diversity & Equality
  • News & Events
  • Webcasts & Presentations
  • Contact Us
  • ©2021 Neurocrine Biosciences, Inc.
  • All Rights Reserved.
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions
  • Accessibility
  • Sitemap

You are now leaving the Neurocrine website.

Neurocrine is not responsible for the content of linked third party websites. Please be aware that the privacy policies and terms of use on these sites are different from Neurocrine policies.

Leave Site

By continuing to use this site, you agree to our use of cookies
as described in our Cookie Policy.